Coherus Oncology, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Coherus Oncology, Inc. (CHRS) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2023-11-06.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2023-11-06
- Coherus Oncology, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2022-09-30 was $0.00.
- Coherus Oncology, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2022-06-30 was $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $0.00 derived: sum of 2 quarters · filed 2023-11-06 | $0.00 10-Q · filed 2023-11-06 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |